Skip to content
OpenCapital
Get started

MaxCyte MXCT Free cash flow

Free cash flow at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$816M+126%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
-$48.62M+17.8%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
-$9.86M-462%
Rapid Micro Biosystems logo
Rapid Micro BiosystemsRPID
-$15.45M-64.7%
PDE
Pro-Dex, Inc.PDEX
$1.52M—
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
——

Other financials

Income statement

See full
Revenue$9.7M-7.1%
Gross profit$8.1M-9.1%
Operating income-$6.2M+49.7%
Net income-$4.8M+53.7%
EPS (diluted)-$0.04+60.0%

Balance sheet

See full
Cash & equivalents$14.6M-37.8%
Total debt$17.5M-7.1%
Total equity$167.9M-15.8%
Total assets$194.5M-15.4%

Cash flow

See full
Operating cash flow-$8.2M+43.3%
CapEx$72.0K-89.0%

Valuation

See full
Market cap$130.15M-46.8%
Enterprise value$133.08M-46.3%
P/S4×-2.8×

Profitability

See full
Gross margin80.5%-0.4pp
Operating margin-141.8%+6.4pp
Net margin-121.2%+12.3pp
FCF margin-90.9%+3.7pp

Returns & leverage

See full
Return on equity-21.3%+2.0pp
Debt / equity0.1×0.0×
Current ratio12×-0.2×

Where this comes from

Calculated from MaxCyte’s reported figures.

−$8.2Mnet cash from operating−$72.0Kcapital expenditures=-$8.24M

The official record: MaxCyte’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about MaxCyte's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MaxCyte's free cash flow?
MaxCyte (MXCT) reported free cash flow of -$8.24M in Q1 2026.
How has MaxCyte's free cash flow changed year-over-year?
MaxCyte's free cash flow increased by 45.3% year-over-year, from -$15.06M to -$8.24M.
What is the long-term trend for MaxCyte's free cash flow?
Over 4 years (2021 to 2025), MaxCyte's free cash flow has grown at a 25.7% compound annual growth rate (CAGR), from -$14.51M to -$36.18M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.